The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment

Author(s):  
Anders Wimo ◽  
Bengt Winblad ◽  
Margareta Grafstrom
BMJ ◽  
1998 ◽  
Vol 317 (7163) ◽  
pp. 945-945 ◽  
Author(s):  
T. Dening ◽  
C. Lawton ◽  
R. Levy ◽  
M Evans ◽  
P. Johnstone ◽  
...  

2021 ◽  
Vol 16 (28) ◽  
pp. 288
Author(s):  
Mariana Dias ◽  
Valmir Moratelli

O artigo tem como objetivo explorar possibilidades narrativas de um narrador-personagem com a Doença de Alzheimer. Tendo como objeto o filme Meu Pai (The Father, 2020), discute-se as escolhas textuais e imagéticas para a imersão do espectador na dualidade das cenas, além das fragilidades inseridas nos processos mnemônicos do protagonista. Como metodologia, descreve-se o emaranhado narrativo, a partir da definição biomédica da doença, conhecida por atingir a memória do sujeito. Como aspectos conclusivos, aponta-se como a obra audiovisual contribui para compreensão de consequências sociais do Alzheimer, possibilitando criar empatia a respeito desta doença ainda sem cura definitiva.The narrative diretion in the subjectivity of a character with Alzheimer’s: crossroads of uncertainties in the script for the film The FatherAbstractThe article aims to explore narratives of a narrator-character with Alzheimer's Disease. With the object of the film The Father (2020), the textual and imagery choices for the immersion of the spectator in the duality of the scenes are discussed, in addition to the weaknesses inserted in the protagonist's mnemonic processes. As a methodology, we teach the narrative entanglement, from the biomedical definition of the disease, known for reaching the subject's memory. As the conclusive aspects, it is pointed out how an audiovisual work contributes to the understanding of the social consequences of Alzheimer's, making it possible to create empathy about this disease that still has no definitive cure.Keywords: Memory; old age; alzheimer’s.


Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.


Sign in / Sign up

Export Citation Format

Share Document